Form 4: Rajiv Shah Receives Stock Option Grant from Omeros Corp

Director Rajiv Shah was granted a stock option to purchase 15,000 shares of Omeros Corporation common stock on June 6, 2024, as part of the company's non-employee director compensation policy.

Summary

• Rajiv Shah, a director of Omeros Corporation, received a stock option grant on June 6, 2024.
• The option allows Shah to purchase 15,000 shares of Omeros common stock at an exercise price of $3.91.
• This grant is part of Omeros' non-employee director compensation policy, which awards options to directors who have served for at least six months and will continue to serve after the annual meeting.
• The options will fully vest and become exercisable the day before the 2025 annual meeting, contingent on Shah's continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, indicating stability and alignment of interests. It's a neutral event with a slightly positive implication for corporate governance.

Positives

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting of the options being contingent on continued service.

Industry Context

Stock option grants are a common form of compensation for non-employee directors, aligning their interests with those of shareholders and incentivizing them to contribute to the company's long-term success.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry depending on company size, stage of development, and financial performance.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, which are larger and more established, typically offer more substantial compensation packages to their directors compared to smaller, development-stage companies like Omeros.
• The size of the stock option grant (15,000 shares) should be compared to grants made by peer companies to assess its relative value and competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to continue serving the company and contributing to its growth.

Key Dates